GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Asset Turnover

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Asset Turnover : 0.81 (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Parnell Pharmaceuticals Holdings's Revenue for the six months ended in Dec. 2018 was $19.03 Mil. Parnell Pharmaceuticals Holdings's Total Assets for the quarter that ended in Dec. 2018 was $23.55 Mil. Therefore, Parnell Pharmaceuticals Holdings's Asset Turnover for the quarter that ended in Dec. 2018 was 0.81.

Asset Turnover is linked to ROE % through Du Pont Formula. Parnell Pharmaceuticals Holdings's annualized ROE % for the quarter that ended in Dec. 2018 was -1.70%. It is also linked to ROA % through Du Pont Formula. Parnell Pharmaceuticals Holdings's annualized ROA % for the quarter that ended in Dec. 2018 was 0.79%.


Parnell Pharmaceuticals Holdings Asset Turnover Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Asset Turnover Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Asset Turnover
Get a 7-Day Free Trial 0.25 0.37 0.41 0.50 0.81

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Asset Turnover Get a 7-Day Free Trial 0.21 0.37 0.41 0.50 0.81

Competitive Comparison of Parnell Pharmaceuticals Holdings's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Asset Turnover falls into.



Parnell Pharmaceuticals Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Parnell Pharmaceuticals Holdings's Asset Turnover for the fiscal year that ended in Dec. 2018 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=19.031/( (23.092+24.003)/ 2 )
=19.031/23.5475
=0.81

Parnell Pharmaceuticals Holdings's Asset Turnover for the quarter that ended in Dec. 2018 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2018 )/( (Total Assets (Q: Dec. 2017 )+Total Assets (Q: Dec. 2018 ))/ count )
=19.031/( (23.092+24.003)/ 2 )
=19.031/23.5475
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Parnell Pharmaceuticals Holdings's annulized ROE % for the quarter that ended in Dec. 2018 is

ROE %**(Q: Dec. 2018 )
=Net Income/Total Stockholders Equity
=0.186/-10.967
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.186 / 38.062)*(38.062 / 23.5475)*(23.5475/ -10.967)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.49 %*1.6164*-2.1471
=ROA %*Equity Multiplier
=0.79 %*-2.1471
=-1.70 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2018) net income data. The Revenue data used here is two times the semi-annual (Dec. 2018) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Parnell Pharmaceuticals Holdings's annulized ROA % for the quarter that ended in Dec. 2018 is

ROA %(Q: Dec. 2018 )
=Net Income/Total Assets
=0.186/23.5475
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.186 / 38.062)*(38.062 / 23.5475)
=Net Margin %*Asset Turnover
=0.49 %*1.6164
=0.79 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2018) net income data. The Revenue data used here is two times the semi-annual (Dec. 2018) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Parnell Pharmaceuticals Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.